Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Biotechnology Value Fund LP and Cytokinetics Inc (CYTK)

Page 1 of 13

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Fund 0 0 1,458,738 1,458,738 2.9%
Biotechnology Value Fund II 0 0 953,260 953,260 1.9%
Biotechnology Value Trading Fund OS 0 0 260,404 260,404 Less%
BVF Partners OS Ltd 0 0 260,404 260,404 Less%
BVF Partners 0 0 3,266,321 3,266,321 6.4%
BVF Inc 0 0 3,266,321 3,266,321 6.4%
Mark N. Lampert 0 0 3,266,321 3,266,321 6.4%

Page 1 of 13 – SEC Filing

 UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 5
)1

Cytokinetics, Incorporated

 (Name of Issuer)

Common Stock, $0.001 par value per share

 (Title of Class of Securities)

23282W 60 5

 (CUSIP Number)

May 12, 2017

 (Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

1
Follow Cytokinetics Inc (NASDAQ:CYTK)
Trade (NASDAQ:CYTK) Now!
Page 1 of 13
Loading...